Home » Topics » Disease categories and therapies » Nephrology

Nephrology
RSS

Regulus reports updated results from phase Ib study of RGLS-4326 in ADPKD

May 25, 2021

New phase Ib/IIa study evaluates VB-119 in membranous nephropathy

May 18, 2021

Dosing initiates in phase I study of GFB-024 in severe insulin-resistant diabetic nephropathy

May 14, 2021

Nephraegis Therapeutics to develop NPH-022 for the prevention and treatment of AKI

May 13, 2021

Phase III FIGARO-DKD cardiovascular outcomes study of finerenone meets primary endpoint

May 10, 2021

Benlysta approved in E.U. for active lupus nephritis

May 6, 2021

European Commission approves Sibnayal for distal renal tubular acidosis

May 5, 2021

Topline data presented from first cohort of phase Ib trial of RGLS-4326

May 4, 2021

FDA approves Farxiga for chronic kidney disease

May 3, 2021

Pooled data from the AURORA and AURA-LV trials across lupus nephritis biopsy classes

April 12, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.